Candel Therapeutics (CADL) Retained Earnings (2020 - 2025)

Candel Therapeutics has disclosed Retained Earnings across 6 years of filings, most recently posting -$230.4 million for Q4 2025.

• Retained Earnings for Q4 2025 came in at -$230.4 million, down 19.87% year-over-year; the trailing twelve-month figure through Dec 2025 was -$230.4 million (down 19.87% YoY), and the FY2025 annual result was -$230.4 million, down 19.87% from the prior year.
• Retained Earnings came in at -$230.4 million for Q4 2025 at Candel Therapeutics, down from -$200.9 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$65.7 million in Q2 2021 to a low of -$230.4 million in Q4 2025.
• The 5-year median for Retained Earnings is -$125.9 million (2023), against an average of -$135.0 million.
• Across the five-year window, Retained Earnings sank 81.78% in 2021 and retreated 12.78% in 2025, its largest moves.
• Candel Therapeutics' Retained Earnings stood at -$80.3 million in 2021, then dropped by 23.41% to -$99.1 million in 2022, then slumped by 38.29% to -$137.0 million in 2023, then sank by 40.27% to -$192.2 million in 2024, then fell by 19.87% to -$230.4 million in 2025.
• The last three Retained Earnings figures came in at -$230.4 million (Q4 2025), -$200.9 million (Q3 2025), and -$189.6 million (Q2 2025), per Business Quant data.